Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant



Status:Recruiting
Conditions:Other Indications
Therapuetic Areas:Other
Healthy:No
Age Range:18 - Any
Updated:6/16/2016
Start Date:August 2015
End Date:June 2016
Contact:Hemant Misra, PhD
Email:hmisra@prolongpharma.com
Phone:908-444-4653

Use our guide to learn which trials are right for you!

A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant

Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in
patients who will be recipients of a donation after brain death (DBD) donor kidney.

Phase 2: Sixty (60) adult subjects who will be recipients of a donation after brain death
(DBD) donor kidney and who meet all eligibility criteria will be randomized 1:1 within 48
hours prior to transplant surgery to receive: two infusions of SANGUINATE at a dose of 320
mg/kg or placebo on the day of surgery and approximately 24 hours after surgery. Patients
will be hospitalized for up to 5 days and the study duration will be 30 days. Results will
be used to inform the study design characteristics for Phase III, including sample size.

Phase III: The same inclusion/exclusion requirements, dosing schedule, hospitalization stay
and outpatient visits as in Phase II with additional visits scheduled at Day 90, Day 180 and
Day 365. Study duration will be 365 days.

Inclusion Criteria:

1. Able to understand and provide written informed consent.

2. Male or female subject at least 18 years of age.

3. Dialysis-dependent renal failure initiated at least 3 months prior to
transplantation.

4. Subject is to be the recipient of a first kidney transplant from a deceased donor
(brain death criteria).

5. Is able to receive intravenous infusions of study drug.

6. Anticipated donor organ cold ischemia time < 30 hours.

7. A calculated prediction of DGF risk of least 25%.

8. Females of childbearing potential must agree to use 2 forms of effective birth
control regimen (at least one-barrier method) during the initial 30-day study period.

9. Male subjects must agree to use condoms or other suitable means of pregnancy
prevention.

Exclusion Criteria:

1. Has received a blood transfusion of packed red blood cells (PRBC), other than with
leukocyte-poor blood, within the 90-day period prior to screening.

2. Recipient of a live donor kidney or a kidney from a donation after cardiac death
(DCD) donor.

3. Recipient of donor kidney preserved with normothermic machine perfusion.

4. Is scheduled to undergo multi-organ transplantation.

5. Has planned transplant of kidney(s) from a donor < 6 years of age.

6. Has planned transplant of kidneys that are implanted en bloc (dual kidney
transplant).

7. Has planned transplant of dual kidneys (from the same donor) transplanted not en
bloc.

8. Body Mass Index (BMI) > 38 kg/m2

9. Is scheduled for transplantation of a kidney from a donor who is known to have
received an investigational therapy (under another Investigational New Drug) for
ischemic/reperfusion injury immediately prior to organ recovery.

10. Is scheduled to receive an blood type-incompatible donor kidney.

11. Has undergone desensitization to remove antibodies prior to transplantation.

12. Total bilirubin > 1.5 mg per dL, transaminase more than twice the upper limit of
normal or evidence of hepatic insufficiency

13. Has participated in an investigational study within the last 30 days or received an
investigational product within 5 half-lives of the study drug administration,
whichever is longest. Potential subjects participating in a strictly observational
study or a study involving approved treatments should be discussed with the Medical
Monitor.

14. Has a history of human immunodeficiency virus (HIV)

15. History or presence of active substance abuse (illicit drugs or alcohol) in the
previous 6 months, as believed by the Investigator

16. Presence of ECG-based evidence of acute myocardial infarction, unstable angina,
decompensated heart failure, third degree heart block or cardiac arrhythmia
associated with hemodynamic instability

17. History or presence of any disease or psychiatric condition that in the
Investigator's assessment that would increase the risk to subjects associated with
study participation, drug administration or interpretation of results

18. History of biopsy-confirmed malignancy within 5 years of randomization, with the
exception of adequately treated basal cell or squamous cell carcinoma in situ skin
lesions, carcinoma of the cervix in situ, or early detected prostate cancer.

19. Female subject who is pregnant or breast feeding.
We found this trial at
21
sites
Chicago, Illinois 60612
Phone: 312-996-5695
?
mi
from
Chicago, IL
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Phone: 216-444-0393
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Phone: 310-794-8516
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
(813) 844-7000
Phone: 813-971-6000
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Augusta, Georgia 30912
Phone: 706-721-2861
?
mi
from
Augusta, GA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Phone: 843-792-3368
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Phone: 312-695-4457
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Phone: 313-916-7178
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Harrisburg, Pennsylvania 17104
Phone: 717-231-8700
?
mi
from
Harrisburg, PA
Click here to add this to my saved trials
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Phone: 713-441-6174
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
?
mi
from
Houston, TX
Click here to add this to my saved trials
94 Old Short Hills Road
Livingston, New Jersey 07039
(973) 322-5000
Phone: 973-322-2146
Saint Barnabas Medical Center As a Barnabas Health facility, Saint Barnabas Medical Center is committed...
?
mi
from
Livingston, NJ
Click here to add this to my saved trials
Madison, Wisconsin 53792
(608) 263-2400
Phone: 608-263-2527
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
1514 Jefferson Hwy.
New Orleans, Louisiana 70121
504-842-3000
Phone: 504-842-8332
Ochsner Medical Center Ochsner Medical Center is located near uptown New Orleans and includes acute...
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phoenix, Arizona 85054
Phone: 480-342-1010
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15260
Phone: 412-647-5738
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
San Diego, California 92123
Phone: 858-637-4800
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Francisco, California 94143
Phone: 415-353-1898
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
45 Castro Street
San Francisco, California 94114
(415) 600-6000
Phone: 415-600-1063
California Pacific Medical Center California Pacific Medical Center is one of the largest private, not-for-profit,...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
2801 W. Bancroft
Toledo, Ohio 43606
419.530.4636
University of Toledo The University of Toledo is one of 14 state universities in Ohio....
?
mi
from
Toledo, OH
Click here to add this to my saved trials
2801 W. Bancroft
Toledo, Ohio 43606
419.530.4636
Phone: 267-300-2275
University of Toledo The University of Toledo is one of 14 state universities in Ohio....
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Washington, District of Columbia 20007
Phone: 202-444-0753
?
mi
from
Washington,
Click here to add this to my saved trials